Effects of a monoclonal anti-acetylcholine receptor antibody on the avian end-plate

Research output: Contribution to journalArticle

24 Citations (Scopus)

Abstract

The effects of anti-acetylcholine receptor (AChR) monoclonal antibodies (mAbs) 370 and 132A on miniature end-plate potentials (MEPPs) and end-plate currents (EPCs) in the posterior lattisimus dorsi muscle of adult chickens were investigated. After incubation of the electrophysiological preparation with mAb 370 (5-50 μg/ml), which blocks both agonist (carbamylcholine) and α-bungarotoxin (α-BTX) binding and induces a hyperacute form of experimental autoimmune myasthenia gravis (EAMG), MEPP and EPC amplitudes were irreversibly reduced. This effect was not associated with any significant change in the time constant describing EPC decay (τ(EPC)), current reversal potential, or the voltage dependence of τ(EPC). The τ(EPC) at -80 mV was 5.9 ± 0.6 ms before incubation with mAb 370 (50 μg/ml) and 6.0 ± 0.9 ms afterwards. Current reversal potential was -3.9 ± 0.4 mV before mAb incubation and -4.8 ± 1.5 mV afterwards. The change in membrane potential required to produce an e-fold change in τ(EPC) was 128 ± 2.3 mV before antibody incubation compared to 125 ± 6.6 mV after incubation. A second anti-AChR mAb, 132A (50 μg/ml), which is capable of inducing the classically described form of EAMG without blocking agonist or α-BTX binding, or inducing hyperacute EAMG, produced no significant change in MEPP amplitude, EPC amplitude τ(EPC) or EPC reversal potentials. The mAb 370 (50 μg/ml) induced a partially reversible decrease of the quantal content of the neurally evoked end-plate potential (EPP). This effect was not observed with mAb 132A, (+)tubocurarine (10-7 - 10-5 g/ml) or an irrelevant anti-oestrogen receptor mAb. These data suggest that the rapid onset of weakness observed in chicken hatchlings after the injection of mAb 370 (Gomez & Richman, 1983) can be attributed to a combined effect of a block of acetylcholine (ACh)-induced ion channel activity in the postsynaptic membrane and a reduction of the neutrally evoked release of acetylcholine from the nerve terminal.

Original languageEnglish (US)
Pages (from-to)271-283
Number of pages13
JournalJournal of Physiology
Volume411
StatePublished - 1989
Externally publishedYes

Fingerprint

Autoimmune Experimental Myasthenia Gravis
Miniature Postsynaptic Potentials
Cholinergic Receptors
Acetylcholine
Antibodies
Chickens
Bungarotoxins
Tubocurarine
Excitatory Postsynaptic Potentials
Carbachol
Ion Channels
Estrogen Receptors
Membrane Potentials
Monoclonal Antibodies
Muscles
Injections
Membranes

ASJC Scopus subject areas

  • Physiology

Cite this

Effects of a monoclonal anti-acetylcholine receptor antibody on the avian end-plate. / Maselli, Ricardo A; Nelson, D. J.; Richman, David P.

In: Journal of Physiology, Vol. 411, 1989, p. 271-283.

Research output: Contribution to journalArticle

@article{5db68d1c4cff4d2f930c2f63c83a05a6,
title = "Effects of a monoclonal anti-acetylcholine receptor antibody on the avian end-plate",
abstract = "The effects of anti-acetylcholine receptor (AChR) monoclonal antibodies (mAbs) 370 and 132A on miniature end-plate potentials (MEPPs) and end-plate currents (EPCs) in the posterior lattisimus dorsi muscle of adult chickens were investigated. After incubation of the electrophysiological preparation with mAb 370 (5-50 μg/ml), which blocks both agonist (carbamylcholine) and α-bungarotoxin (α-BTX) binding and induces a hyperacute form of experimental autoimmune myasthenia gravis (EAMG), MEPP and EPC amplitudes were irreversibly reduced. This effect was not associated with any significant change in the time constant describing EPC decay (τ(EPC)), current reversal potential, or the voltage dependence of τ(EPC). The τ(EPC) at -80 mV was 5.9 ± 0.6 ms before incubation with mAb 370 (50 μg/ml) and 6.0 ± 0.9 ms afterwards. Current reversal potential was -3.9 ± 0.4 mV before mAb incubation and -4.8 ± 1.5 mV afterwards. The change in membrane potential required to produce an e-fold change in τ(EPC) was 128 ± 2.3 mV before antibody incubation compared to 125 ± 6.6 mV after incubation. A second anti-AChR mAb, 132A (50 μg/ml), which is capable of inducing the classically described form of EAMG without blocking agonist or α-BTX binding, or inducing hyperacute EAMG, produced no significant change in MEPP amplitude, EPC amplitude τ(EPC) or EPC reversal potentials. The mAb 370 (50 μg/ml) induced a partially reversible decrease of the quantal content of the neurally evoked end-plate potential (EPP). This effect was not observed with mAb 132A, (+)tubocurarine (10-7 - 10-5 g/ml) or an irrelevant anti-oestrogen receptor mAb. These data suggest that the rapid onset of weakness observed in chicken hatchlings after the injection of mAb 370 (Gomez & Richman, 1983) can be attributed to a combined effect of a block of acetylcholine (ACh)-induced ion channel activity in the postsynaptic membrane and a reduction of the neutrally evoked release of acetylcholine from the nerve terminal.",
author = "Maselli, {Ricardo A} and Nelson, {D. J.} and Richman, {David P}",
year = "1989",
language = "English (US)",
volume = "411",
pages = "271--283",
journal = "Journal of Physiology",
issn = "0022-3751",
publisher = "Wiley-Blackwell",

}

TY - JOUR

T1 - Effects of a monoclonal anti-acetylcholine receptor antibody on the avian end-plate

AU - Maselli, Ricardo A

AU - Nelson, D. J.

AU - Richman, David P

PY - 1989

Y1 - 1989

N2 - The effects of anti-acetylcholine receptor (AChR) monoclonal antibodies (mAbs) 370 and 132A on miniature end-plate potentials (MEPPs) and end-plate currents (EPCs) in the posterior lattisimus dorsi muscle of adult chickens were investigated. After incubation of the electrophysiological preparation with mAb 370 (5-50 μg/ml), which blocks both agonist (carbamylcholine) and α-bungarotoxin (α-BTX) binding and induces a hyperacute form of experimental autoimmune myasthenia gravis (EAMG), MEPP and EPC amplitudes were irreversibly reduced. This effect was not associated with any significant change in the time constant describing EPC decay (τ(EPC)), current reversal potential, or the voltage dependence of τ(EPC). The τ(EPC) at -80 mV was 5.9 ± 0.6 ms before incubation with mAb 370 (50 μg/ml) and 6.0 ± 0.9 ms afterwards. Current reversal potential was -3.9 ± 0.4 mV before mAb incubation and -4.8 ± 1.5 mV afterwards. The change in membrane potential required to produce an e-fold change in τ(EPC) was 128 ± 2.3 mV before antibody incubation compared to 125 ± 6.6 mV after incubation. A second anti-AChR mAb, 132A (50 μg/ml), which is capable of inducing the classically described form of EAMG without blocking agonist or α-BTX binding, or inducing hyperacute EAMG, produced no significant change in MEPP amplitude, EPC amplitude τ(EPC) or EPC reversal potentials. The mAb 370 (50 μg/ml) induced a partially reversible decrease of the quantal content of the neurally evoked end-plate potential (EPP). This effect was not observed with mAb 132A, (+)tubocurarine (10-7 - 10-5 g/ml) or an irrelevant anti-oestrogen receptor mAb. These data suggest that the rapid onset of weakness observed in chicken hatchlings after the injection of mAb 370 (Gomez & Richman, 1983) can be attributed to a combined effect of a block of acetylcholine (ACh)-induced ion channel activity in the postsynaptic membrane and a reduction of the neutrally evoked release of acetylcholine from the nerve terminal.

AB - The effects of anti-acetylcholine receptor (AChR) monoclonal antibodies (mAbs) 370 and 132A on miniature end-plate potentials (MEPPs) and end-plate currents (EPCs) in the posterior lattisimus dorsi muscle of adult chickens were investigated. After incubation of the electrophysiological preparation with mAb 370 (5-50 μg/ml), which blocks both agonist (carbamylcholine) and α-bungarotoxin (α-BTX) binding and induces a hyperacute form of experimental autoimmune myasthenia gravis (EAMG), MEPP and EPC amplitudes were irreversibly reduced. This effect was not associated with any significant change in the time constant describing EPC decay (τ(EPC)), current reversal potential, or the voltage dependence of τ(EPC). The τ(EPC) at -80 mV was 5.9 ± 0.6 ms before incubation with mAb 370 (50 μg/ml) and 6.0 ± 0.9 ms afterwards. Current reversal potential was -3.9 ± 0.4 mV before mAb incubation and -4.8 ± 1.5 mV afterwards. The change in membrane potential required to produce an e-fold change in τ(EPC) was 128 ± 2.3 mV before antibody incubation compared to 125 ± 6.6 mV after incubation. A second anti-AChR mAb, 132A (50 μg/ml), which is capable of inducing the classically described form of EAMG without blocking agonist or α-BTX binding, or inducing hyperacute EAMG, produced no significant change in MEPP amplitude, EPC amplitude τ(EPC) or EPC reversal potentials. The mAb 370 (50 μg/ml) induced a partially reversible decrease of the quantal content of the neurally evoked end-plate potential (EPP). This effect was not observed with mAb 132A, (+)tubocurarine (10-7 - 10-5 g/ml) or an irrelevant anti-oestrogen receptor mAb. These data suggest that the rapid onset of weakness observed in chicken hatchlings after the injection of mAb 370 (Gomez & Richman, 1983) can be attributed to a combined effect of a block of acetylcholine (ACh)-induced ion channel activity in the postsynaptic membrane and a reduction of the neutrally evoked release of acetylcholine from the nerve terminal.

UR - http://www.scopus.com/inward/record.url?scp=0024504675&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0024504675&partnerID=8YFLogxK

M3 - Article

C2 - 2614725

AN - SCOPUS:0024504675

VL - 411

SP - 271

EP - 283

JO - Journal of Physiology

JF - Journal of Physiology

SN - 0022-3751

ER -